158 related articles for article (PubMed ID: 23231927)
1. MSH2 and CXCR4 involvement in malignant VIPoma.
Müller S; Kupka S; Königsrainer I; Northoff H; Sotlar K; Bock T; Kandolf R; Traub F; Königsrainer A; Zieker D
World J Surg Oncol; 2012 Dec; 10():264. PubMed ID: 23231927
[TBL] [Abstract][Full Text] [Related]
2. Ventricular fibrillation resulting from electrolyte imbalance reveals vipoma in MEN1 syndrome.
Cavalli T; Giudici F; Santi R; Nesi G; Brandi ML; Tonelli F
Fam Cancer; 2016 Oct; 15(4):645-9. PubMed ID: 27071757
[TBL] [Abstract][Full Text] [Related]
3. Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male.
Abu-Zaid A; Azzam A; Abudan Z; Algouhi A; Almana H; Amin T
Hematol Oncol Stem Cell Ther; 2014 Sep; 7(3):109-15. PubMed ID: 24785507
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic VIPomas: subject review and one institutional experience.
Ghaferi AA; Chojnacki KA; Long WD; Cameron JL; Yeo CJ
J Gastrointest Surg; 2008 Feb; 12(2):382-93. PubMed ID: 17510774
[TBL] [Abstract][Full Text] [Related]
5. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors.
Barghorn A; Speel EJ; Farspour B; Saremaslani P; Schmid S; Perren A; Roth J; Heitz PU; Komminoth P
Am J Pathol; 2001 Jun; 158(6):1903-11. PubMed ID: 11395364
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.
Case CC; Wirfel K; Vassilopoulou-Sellin R
Med Oncol; 2002; 19(3):181-7. PubMed ID: 12482130
[TBL] [Abstract][Full Text] [Related]
7. Vasoactive intestinal polypeptide secreting pancreatic tumour with hepatic metastases: long term survival after orthotopic liver transplantation.
Johnston PC; Ardill JE; Johnston BT; Mc Cance DR
Ir J Med Sci; 2010 Sep; 179(3):439-41. PubMed ID: 18825477
[TBL] [Abstract][Full Text] [Related]
8. Radiofrequency ablation has a valuable therapeutic role in metastatic VIPoma.
Moug SJ; Leen E; Horgan PG; Imrie CW
Pancreatology; 2006; 6(1-2):155-9. PubMed ID: 16354964
[TBL] [Abstract][Full Text] [Related]
9. Partial loss of heterozygosity events at the mutated gene in tumors from MLH1/MSH2 large genomic rearrangement carriers.
Zavodna K; Krivulcik T; Bujalkova MG; Slamka T; Martinicky D; Ilencikova D; Bartosova Z
BMC Cancer; 2009 Nov; 9():405. PubMed ID: 19930554
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D; Mastoraki A; Bagias G; Patras R; Moris D; Lazaridis II; Arkadopoulos N; Felekouras E
J BUON; 2019; 24(2):415-423. PubMed ID: 31127985
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic VIPomas from China: Case reports and literature review.
Chen C; Zheng Z; Li B; Zhou L; Pang J; Wu W; Zheng C; Zhao Y
Pancreatology; 2019 Jan; 19(1):44-49. PubMed ID: 30391116
[TBL] [Abstract][Full Text] [Related]
12. Elevated microsatellite alterations at selected tetranucleotides (EMAST) and mismatch repair gene expression in prostate cancer.
Burger M; Denzinger S; Hammerschmied CG; Tannapfel A; Obermann EC; Wieland WF; Hartmann A; Stoehr R
J Mol Med (Berl); 2006 Oct; 84(10):833-41. PubMed ID: 16924473
[TBL] [Abstract][Full Text] [Related]
13. Massive amyloid deposition in pancreatic vipoma: a case report.
Crowley PF; Slavin JL; Rode J
Pathology; 1996 Nov; 28(4):377-9. PubMed ID: 9007963
[TBL] [Abstract][Full Text] [Related]
14. VIPoma with multiple endocrine neoplasia type 1 identified as an atypical gene mutation.
Fujiya A; Kato M; Shibata T; Sobajima H
BMJ Case Rep; 2015 Nov; 2015():. PubMed ID: 26564120
[TBL] [Abstract][Full Text] [Related]
15. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene.
Banville N; Geraghty R; Fox E; Leahy DT; Green A; Keegan D; Geoghegan J; O'Donoghue D; Hyland J; Sheahan K
Hum Pathol; 2006 Nov; 37(11):1498-502. PubMed ID: 16996571
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of symptoms and reduction of VIP levels after hepatic artery chemoembolization in a patient with sandostatin resistant VIPoma.
Shaib W; Mitchell K; Saif MW
Yale J Biol Med; 2010 Mar; 83(1):27-33. PubMed ID: 20351979
[TBL] [Abstract][Full Text] [Related]
17. Multiplex SNaPshot genotyping for detecting loss of heterozygosity in the mismatch-repair genes MLH1 and MSH2 in microsatellite-unstable tumors.
Bujalkova M; Zavodna K; Krivulcik T; Ilencikova D; Wolf B; Kovac M; Karner-Hanusch J; Heinimann K; Marra G; Jiricny J; Bartosova Z
Clin Chem; 2008 Nov; 54(11):1844-54. PubMed ID: 18772310
[TBL] [Abstract][Full Text] [Related]
18. Genetic changes of MLH1 and MSH2 genes could explain constant findings on microsatellite instability in intracranial meningioma.
Pećina-Šlaus N; Kafka A; Bukovac A; Vladušić T; Tomas D; Hrašćan R
Tumour Biol; 2017 Jul; 39(7):1010428317705791. PubMed ID: 28705114
[TBL] [Abstract][Full Text] [Related]
19. Giant metastatic VIPoma in the liver.
Dohmen K; Fukushima N; Fujisaki T; Iwakiri R; Yamano Y; Nagano M; Wada K; Kodama K; Iwata Y; Hachimine K
Gastroenterol Jpn; 1991 Aug; 26(4):530-5. PubMed ID: 1655553
[TBL] [Abstract][Full Text] [Related]
20. Vasoactive intestinal polypeptide-secreting tumours: biology and therapy.
Park SK; O'Dorisio MS; O'Dorisio TM
Baillieres Clin Gastroenterol; 1996 Dec; 10(4):673-96. PubMed ID: 9113317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
